Histone Deacetylase Inhibitors as a Tool to Up-Regulate New Fungal Biosynthetic Products: Isolation of EGM-556, a Cyclodepsipeptide, from Microascus sp.
Organic Letters2010Vol. 13(3), pp. 410–413
Citations Over TimeTop 10% of 2010 papers
Abstract
The histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) was used to turn on the biosynthesis of EGM-556, a new cyclodepsipeptide of hybrid biosynthetic origin, isolated from the Floridian marine sediment-derived fungus Microascus sp. The absolute configurations of three chiral centers were determined by Marfey's derivatization. EGM-556 represents one of the few examples in which silent biosynthetic genes, encoding a new secondary metabolite, were activated by means of epigenetic manipulation of the fungal metabolome.
Related Papers
- → A Review of Depsipeptide and Other Histone Deacetylase Inhibitors in Clinical Trials(2004)176 cited
- → Macrolactamization versus Macrolactonization: Total Synthesis of FK228, the Depsipeptide Histone Deacetylase Inhibitor(2008)61 cited
- → Depsipeptide (FK228) as a Novel Histone Deacetylase Inhibitor: Mechanism of Action and Anticancer Activity(2007)26 cited
- → The Bicyclic Depsipeptide Family of Histone Deacetylase Inhibitors(2007)10 cited
- Global gene expression profile in human colon cancer HCT-116 cells in combination with 5-fluorouracil and histone deacetylase inhibitor, depsipeptide(2015)